AVEO Pharmaceuticals is a biopharmaceutical company. The company's product candidates include: tivozanib, its key candidate, a vascular endothelial growth factor receptor tyrosine kinase inhibitor which has been investigated in several tumor types, including renal cell, hepatocellular, colorectal and breast cancers; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which is being tested for the treatment of squamous cell carcinoma of the head and neck, acute myeloid leukemia, and pancreatic cancer; AV-203, an anti-ErbB3 specific monoclonal antibody with high ErbB3 affinity; and AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia.

International Flavors & Fragrances is a creator and manufacturer of taste, scent and complementary adjacent products, including cosmetic active and natural health ingredients. The company's operating segments are Taste and Scent. The Taste segment develops a range of different flavors and taste offerings for its customers, most of which are tailor-made. The company's Taste business is comprised of various portfolios across flavor compounds, savory solutions, inclusions and nutrition and specialty ingredients. The Scent segment creates fragrance compounds and fragrance ingredients for the household and personal care products. The company also produces cosmetic active and functional ingredients for use in cosmetics.

IntriCon is is an international company engaged in designing, developing, engineering and manufacturing miniature interventional, implantable and body-worn medical devices. The company serves as a joint development manufacturing partner to medical device original equipment manufacturers by designing, developing, engineering, manufacturing and distributing micro-miniature products, microelectronics, micro-mechanical assemblies, assemblies and software solutions, primarily for markets, such as diabetes, drug delivery, surgical navigation, and hearing health.

Opko Health is a healthcare company. The company manages two segments: Diagnostics, which provides laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional healthcare; and Pharmaceutical, which includes Rayaldee for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease (CKD) and vitamin D insufficiency, and Alpharen (Fermagate Tablets) for the treatment of hyperphosphatemia in CKD patients requiring regular hemodialysis.

Otelco provides a range of telecommunication services on a retail and wholesale basis. These services include local and long distance calling; network access to and from the company's customers; data transport; digital high-speed internet; cable and Internet Protocol television; other telephone related services; and cloud hosting and managed services. The company provides various communications services that are sold to economically similar customers in a comparable manner of distribution. The company also provides cloud hosting and managed services for small and mid-sized companies who rely on mission-critical software applications.

Ultimate Software Group is a provider of cloud-based human capital management solutions, often referred to as human capital management (HCM). The company's UltiPro product suite (UltiPro) is a solution that has human resources, payroll, and benefits management and includes global people management. The solution is delivered via software-as-a-service to organizations based in the U.S. and Canada, including those with global workforces. UltiPro is designed to manage the employee life cycle from recruitment to retirement. The company's cloud offering of UltiPro provides Web-based access to HCM functionality for organizations that want to simplify delivery and support of their business applications.